[The Role of MiR-709 in Erythroid Development and Its Correlation with Multiple Hematological Diseases]

To investigate the role of microRNA-709 (miR-709 ) in erythroid development and its correlation with multiple hematological diseases.

The expression of miR-709 in multiple tissues of mice was detected by qRT-PCR; The expression of miR-709 and other miRNAs in day-14.5 fetal liver cells from mouse embryos was detected by transcriptome microarray analysis; The expression of miR-709 in nucleated red blood cells derived from bone marrow and spleen, and in peripheral blood erythrocytes of mice was detected by magnetic bead sorting combined with qRT-PCR; The expression of miR-709 during erythroid differentiation of murine erythroleukemia (MEL) cells was analyzed by cell culture and qRT-PCR; The expression of miR-709 during erythroid lineage differentiation of mouse erythroid precursor cells derived from fetal livers was analyzed by magnetic bead sorting, flow cytometry, cell culture and qRT-PCR; The expression of miR-709 in peripheral blood of patients with different hematological diseases was measured by qRT-PCR.

Among the various tissues examined in mice, miR-709 exhibited the highest expression in peripheral blood, followed by high expression levels in muscle, bone marrow, and liver; In day-14.5 fetal liver cells from mouse embryos, miR-709 was highly expressed, significantly surpassing miR-451, which was most highly expressed in mature red blood cells; In nucleated red blood cells derived from mouse bone marrow and spleen, the expression of miR-709 was higher than that of miR-451 , whereas the opposite pattern was observed in peripheral blood; During the differentiation of erythroid precursor cells derived from mouse embryonic liver, the expression level of miR-709 first increased and then decreased; During the differentiation of MEL cells, the expression of miR-709 gradually increased; Compared with the healthy controls, patients with myelodysplastic syndrome (MDS), α-thalassemia and β-thalassemia expressed lower levels of miR-709 in peripheral blood; while the expression of miR-709 in patients with infectious hemolytic anemia (IHA) was higher than that in healthy controls.

miR-709 is highly expressed in the early stage of erythropoiesis and exhibits dynamic changes during erythroid development, potentially playing an important role. It is also differentially expressed in different hematological diseases, which is expected to serve as a promising biomarker and therapeutic target in the clinical diagnosis and treatment of hematological diseases.